Public

On December 1st, 2023, $NEXI surged over 300%, leading Nasdaq to halt trading. 

NexImmune has faced a significant decline since its 2021 IPO. 

With concerns about dissolution, $NEXI didn't trade on Friday.

NexImmune proposes on December 21 meeting for shareholder approval of liquidation. The board unanimously supports dissolution after evaluating strategic options and the company's financial status.

Trouble emerged in September with NexImmune reducing its workforce and pausing clinical trials. 

Despite this, $NEXI surged 35% between November 27 and 30, prompting Nasdaq's intervention.

Neximmune Inc

Attorney Investigation

Mismanagement

Misleading Statements

Omissions

Directors

Management

NexImmune (NEXI) Stock Halted Case

neximmune-investors-lawsuit

Stocks

Long

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.

NexImmune (NEXI) Stock Halted Case

Collecting participants…